ClinicalTrials.gg
Not yet recruitingNCT07557407Updated Apr 29, 2026

A Mass Balance Study of [14C]HRS-1780 in Healthy Adult Male Subjects

A Phase 1 interventional study of [14C]HRS-1780 in Chronic Kidney Diseases, sponsored by Shandong Suncadia Medicine Co., Ltd.. Not yet recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 245 studies in Renal Insufficiency, Chronic with a site in China — 94 open to participants now, 107 under way, 17 of them phase 3. Renal Insufficiency, Chronic · China.

Planned enrollment
158th of 164
6 · median 182
Started
2026
with 26 others
Phase 1
20 of 245
10 open now
Primary completion
2026-06
later than 33 of 106 live
Registered
226th of 245
by date
Lead sponsor
6 of 245
Shandong Suncadia Medicine Co., Ltd.

Among the 245 studies in Renal Insufficiency, Chronic with a site in China, this one is the 158th largest by planned enrollment of the 164 interventional ones that give a count, is one of 27 that started in 2026, is one of 20 in phase 1, reaches primary completion later than 33 of the 106 other live ones, and was the 226th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

94 of the 245 studies in Renal Insufficiency, Chronic with a site in China are open now. Recruiting first, the newest first:

89 more — sign in →

All 94 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Renal Insufficiency, Chronic with a site in China, or all of them as a file.
02

Study summary

The study aims to evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite identification of [14C]HRS-1780 following an oral single dose in healthy adult male participants.

03

Conditions studied

  • Chronic Kidney Diseases
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Before the trial, sign the form, fully understand the trial content, process and possible adverse reactions, and be willing to complete the research as required by the trial protocol.
  2. Aged 18 to 45 years old (inclusive) who are in good health and have signed the informed consent form on that day.
  3. Body weight of no less than 50 kg and a (BMI) within the range of 19.0 to 26.0 kg/m2 (inclusive).
  4. Participants (including their partners) shall have no intention to have children or donate sperm within three months after signing the informed consent form and shall voluntarily adopt the measures stipulated in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. abnormalities in vital signs (complete physical examination, laboratory tests, biochemistry, urinalysis, coagulation function, stool routine and occult blood, thyroid function), 12-lead , digital rectal examination, chest X-rays, abdominal ultrasound.
  2. Positive virus (HBsAg), hepatitis B core antibody (HbcAb), virus (HCV Ab), (HIV), or syphilis at screening.
  3. Receipt of medical devices or another drug (including placebo) within the previous 3 months or within the 5 half-lives (whichever is longer), and plan to participate in other clinical trials of drugs or medical devices during the trial period.
  4. History of illicit or prescription drug abuse in the past five years or drug addiction within 3 months of screening, or positive urine drug screen at screening/baseline.
  5. Use of any prescription medicine within 2 weeks, or over-the-counter (OTC) medicine, herbal remedy, or nutritional supplement, or within 5 half-lives of any drugs, whichever is longer prior to dosing, except for vitamins and occasional use of paracetamol (≤ 2 g/day; no more than 3 consecutive days).
  6. History or evidence of clinically significant disorders (including but not limited to immunologic, hepatic, renal, digestive, urinary, psychiatric, respiratory, hematologic, endocrine, or metabolic disorders) and deemed not suitable to participate in the study by the investigator.
  7. Severe systemic infections, injuries, or major surgeries as determined by the investigator within 3 months prior to screening, or plan to do surgeries during the study.
  8. Whole blood/plasma donation or loss ≥ 200 mL of blood within 3 months prior to dosing; received a blood/plasma transfusion.
  9. Alcohol abuse or consumption of more than 14 units of alcohol per week within the previous 6 months (1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine); or those who have taken alcohol-containing products within 48 hours before administration; or those with a positive alcohol breath test at baseline; or those who were unable to abstain from alcohol during the trial.
  10. History of excessive smoking in the past 1 month prior to screening which is defined as more than 5 cigarettes daily (or products with an equivalent amount of nicotine); or positive cotinine test at baseline, or unable to abstain from smoking within 48 h prior to D-1/check-in and during the trial.
  11. Receipt of a vaccine within 2 weeks prior to administration or are scheduled to receive a vaccine during the study period and within 1 month after administration.
  12. Any other circumstances (e.g., not suitable for venous access) or laboratory abnormality that, in the investigator's judgment, may increase the risk to the participant, or be associated with the participant's participation in and completion of the study or could preclude the evaluation of the participant's response.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    [14C]HRS-1780 Group

    Oral, single dose.

    Drug: [14C]HRS-1780

Interventions

06

What researchers measure

Primary outcomes

  1. Total radioactivity ratio of whole blood/plasma.

    Time frame: 0 to anticipated 11 days.

  2. Tmax

    Time to reach maximum concentration (Tmax).

    Time frame: 0 to anticipated 11 days.

  3. Cmax

    Maximum concentration (Cmax).

    Time frame: 0 to anticipated 11 days.

  4. AUClast

    Area under the concentration time curve from time point 0 to the last quantifiable time point (AUClast).

    Time frame: 0 to anticipated 11 days.

  5. AUC0-inf

    Area under the concentration curve from time 0 to extrapolated infinite time (AUC0-inf).

    Time frame: 0 to anticipated 11 days.

  6. t1/2

    Half-life (t1/2).

    Time frame: 0 to anticipated 11 days.

  7. CL/F

    Apparent clearance (CL/F).

    Time frame: 0 to anticipated 11 days.

  8. Vz/F

    Apparent volume of distribution (Vz/F).

    Time frame: 0 to anticipated 11 days.

  9. %AUC

    Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC).

    Time frame: 0 to anticipated 11 days.

  10. %Dose

    Percentage of parent drug and its metabolites in urine and feces as a percentage of administered dose (%Dose).

    Time frame: 0 to anticipated 11 days.

  11. Total radioactivity ratio for blood/plasma.

    Time frame: 0 to anticipated 11 days.

  12. The cumulative recovery amount and recovery rate of total radioactive substances in urine and feces.

    Time frame: 0 to anticipated 11 days.

Secondary outcomes

  1. Safety and tolerability as measured by incidence of adverse events (AEs) and serious AEs.

    Time frame: 0 to anticipated 11 days.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jun 2026, 1 month later.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 1 month is below that.

Counting every sponsor, half of 109 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 29, 2026
StartEst.
May 2026
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07557407
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
May 2026 (estimated)
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Apr 29, 2026

Study contacts

Jing He
Contact
jing.he@hengrui.com
+86-0518-82342973
Yue Fei
Contact
yue.fei@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-1780

Start the discussion